Search Results - "Nonagase, Y"

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment by Haratani, K., Hayashi, H., Tanaka, T., Kaneda, H., Togashi, Y., Sakai, K., Hayashi, K., Tomida, S., Chiba, Y., Yonesaka, K., Nonagase, Y., Takahama, T., Tanizaki, J., Tanaka, K., Yoshida, T., Tanimura, K., Takeda, M., Yoshioka, H., Ishida, T., Mitsudomi, T., Nishio, K., Nakagawa, K.

“…The efficacy of programmed death-1 blockade in epidermal growth factor receptor gene (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) patients with…”
Get full text

Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer by Takeda, M., Sakai, K., Terashima, M., Kaneda, H., Hayashi, H., Tanaka, K., Okamoto, K., Takahama, T., Yoshida, T., Iwasa, T., Shimizu, T., Nonagase, Y., Kudo, K., Tomida, S., Mitsudomi, T., Saigo, K., Ito, A., Nakagawa, K., Nishio, K.

“…The clinical implementation of genomic profiling for lung cancer with high-throughput, multiplex tests is warranted to allow prioritization of appropriate…”
Get full text

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer by Sakiyama, T, Tsurutani, J, Iwasa, T, Kawakami, H, Nonagase, Y, Yoshida, T, Tanaka, K, Fujisaka, Y, Kurata, T, Komoike, Y, Nishio, K, Nakagawa, K

“…Background: We evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, recommended dose for phase II (P2RD), and preliminary anticancer activity…”
Get full text